Pharma Market Access Insights - from Petauri Evidence

64 Folgen

1. Navigating US payer evidence needs to optimise market access

   Vom: 27.11.2024
2. Best practice RWE approaches to support economic modelling for HTA

   Vom: 20.11.2024
3. NHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to Christmas

   Vom: 18.11.2024
4. De-mystifying the NHS – What you need to know about the NHS as a market for your health technology

   Vom: 11.10.2024
5. NHS primary care panel – the GP Contract and Operational Planning Guidance

   Vom: 10.9.2024
6. Engage NHS healthcare decision-makers with RWD

   Vom: 12.8.2024
7. Market access and reimbursement in Canada – changes at CADTH

   Vom: 20.6.2024
8. Rare Disease market access in the MENA and Nordic regions

   Vom: 10.5.2024
9. How does funding flow in NHSE Regions?

   Vom: 9.4.2024
10. NHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024)

    Vom: 9.4.2024
11. De-mystifying health economic model classifications and structures

    Vom: 22.3.2024
12. Evidence strategy for Medical Technologies and Diagnostics

    Vom: 12.3.2024
13. How to set your Pharma or Medtech product up for success in the US market

    Vom: 26.2.2024
14. What's happening with specialised commissioning in the NHS?

    Vom: 12.2.2024
15. Integrated care in NHS Wales – what can England learn from its neighbour?

    Vom: 17.1.2024
16. Market access in Italy: Reforms at AIFA

    Vom: 18.12.2023
17. Unmet need in NHS primary care – How can industry best support PCN leaders?

    Vom: 28.11.2023
18. Population health management: a community effort across health and life sciences

    Vom: 1.11.2023
19. Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access

    Vom: 26.10.2023
20. 6 areas of UK health policy for Medtech to pay attention to

    Vom: 16.10.2023